lifestyle.smarttalksuccess.com

Author: Sironax USA, Inc.

Sironax’s SARM1 Inhibitor SIR2501 Granted FDA Fast Track Designation in Chemotherapy-induced Peripheral Neuropathy (CIPN)

May 11, 2026
Sironax Announces Abstract on SARM1 Inhibitor SIR2501 Selected for Presentation at 2026 ASCO Annual Meeting

May 4, 2026
Sironax Appoints Clive Wang to Board of Directors

May 1, 2026
Sironax Announces Upcoming Poster Presentation on NAMPT Activation

April 30, 2026